Puma Biotechnology (PBYI) PT Raised to $9 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Price: $10.85 -1.54%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 54
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 54
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $9.00 (from $8.00) while maintaining a Sell rating.
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Safran SA (SAF:FP) (SAFRF) PT Lowered to EUR375 at RBC Capital
- Procter & Gamble (PG) PT Raised to $167 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
